Healthcare Takes A Big Step Forward With The Help of A.I.

To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.

Click here to learn more about the booming eHealth industry - and see which microcap will be at the

Michael D. Blaszyk net worth and biography

Michael Blaszyk Biography and Net Worth

Director of ImmunityBio

Michael D. Blaszyk has served as a member of the Board since July 2015. Since July 2017, Mr. Blaszyk has served as an operating partner of Beecken Petty O’Keefe & Company, LLC (BPOC), a capital markets company. Prior to BPOC, he served as the chief financial officer and chief corporate officer of Dignity Health (formerly known as Catholic Healthcare West), a not-for-profit public benefit corporation, from December 2000 until his retirement in December 2015. Prior to joining Dignity Health, he served as the senior vice president and chief financial officer of University Hospitals Health System in Cleveland, Ohio, a healthcare system, from 1997 to 2000. He also previously served as the managing partner of the Northeast Region Health Care Provider Consulting Practice for Mercer LLC (formerly known as William M. Mercer), a global consulting firm, and the executive vice president of Boston Medical Center, a not-for-profit academic medical center. Mr. Blaszyk is a director/manager for Medicus, NantHealth (an affiliate of Dr. Soon-Shiong), Himagine, and Health Management Associates. He received his B.S. in Life Sciences from Wayne State University and his Masters in Health Administration from the University of Colorado. We believe Mr. Blaszyk is qualified to serve as a member of the Board based on his extensive experience with and knowledge of the healthcare industry and his significant financial and accounting background.

What is Michael D. Blaszyk's net worth?: The estimated net worth of Michael D. Blaszyk is at least $203,519.45 as of June 5th, 2023. Mr. Blaszyk owns 71,915 shares of ImmunityBio stock worth more than $203,519 as of December 18th. This net worth evaluation does not reflect any other assets that Mr. Blaszyk may own. Learn More about Michael D. Blaszyk's net worth.
How do I contact Michael D. Blaszyk?: The corporate mailing address for Mr. Blaszyk and other ImmunityBio executives is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. ImmunityBio can also be reached via phone at (858) 633-0300 and via email at [email protected]. Learn More on Michael D. Blaszyk's contact information.
Has Michael D. Blaszyk been buying or selling shares of ImmunityBio?: Michael D. Blaszyk has not been actively trading shares of ImmunityBio during the past quarter. Most recently, on Monday, June 5th, Michael D. Blaszyk bought 71,915 shares of ImmunityBio stock. The stock was acquired at an average cost of $2.75 per share, with a total value of $197,766.25. Following the completion of the transaction, the director now directly owns 71,915 shares of the company's stock, valued at $197,766.25. Learn More on Michael D. Blaszyk's trading history.
Who are ImmunityBio's active insiders?: ImmunityBio's insider roster includes Richard Adcock (CEO), Michael Blaszyk (Director), Cheryl Cohen (Director), David Sachs (CFO), and Barry Simon (Director). Learn More on ImmunityBio's active insiders.

Michael D. Blaszyk Insider Trading History at ImmunityBio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/5/2023	Buy	71,915	$2.75	$197,766.25	71,915

Michael D. Blaszyk Buying and Selling Activity at ImmunityBio

ImmunityBio Company Overview

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Today's Range

Now: $2.83

$2.82

$3.03

50 Day Range

MA: $4.54

$2.83

$6.17

2 Week Range

Now: $2.83

$2.82

$10.53

Volume

10,233,240 shs

Average Volume

4,894,827 shs

Market Capitalization

$1.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86